{
    "clinical_study": {
        "@rank": "165003", 
        "arm_group": [
            {
                "arm_group_label": "Ulipristal acetate 5 mg", 
                "arm_group_type": "Experimental", 
                "description": "Ulipristal acetate 5 mg"
            }, 
            {
                "arm_group_label": "Ulipristal acetate 10 mg", 
                "arm_group_type": "Experimental", 
                "description": "Ulipristal acetate 10 mg"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the superiority of ulipristal acetate vs. placebo for the treatment\n      of bleeding associated with uterine fibroids"
        }, 
        "brief_title": "A Study of the Efficacy and Safety of Ulipristal for the Treatment of Uterine Bleeding Associated With Leiomyomas", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Uterine Bleeding in Women With Leiomyomas", 
        "condition_browse": {
            "mesh_term": [
                "Hemorrhage", 
                "Leiomyoma", 
                "Myofibroma", 
                "Uterine Hemorrhage"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Pre-menopausal women, 18-50 years, inclusive.\n\n          -  Has experienced cyclic abnormal uterine bleeding (heavy or prolonged).\n\n          -  Has a menstrual blood loss (MBL) of \u2265 80 mL as measured once by the alkaline hematin\n             method during screening over the first 8 days of menses.\n\n          -  Has a minimum of one discrete leiomyoma observable by transvaginal ultrasound at the\n             screening assessment\n\n        Exclusion Criteria:\n\n          -  Has a history of uterine surgery that would interfere with the study endpoints.\n\n          -  Has a known coagulation disorder including bleeding disorder or clotting disorder\n             (e.g., von Willebrand disease or platelet disorder, factor V Leiden, prothrombin gene\n             mutation, antiphospholipid syndrome).\n\n          -  Has a history of, or current uterine, cervix, ovarian, or breast cancer."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02147197", 
            "org_study_id": "UL1309"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ulipristal acetate 5 mg", 
                "intervention_name": "Ulipristal acetate 5 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Ulipristal acetate 10 mg", 
                "intervention_name": "Ulipristal acetate 10 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado"
                    }, 
                    "name": "Watson Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lakewood", 
                        "country": "United States", 
                        "state": "Colorado"
                    }, 
                    "name": "Watson Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clearwater", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Watson Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Port Richey", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Watson Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia"
                    }, 
                    "name": "Watson Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Norfolk", 
                        "country": "United States", 
                        "state": "Nebraska"
                    }, 
                    "name": "Watson Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Albuquerque", 
                        "country": "United States", 
                        "state": "New Mexico"
                    }, 
                    "name": "Watson Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Watson Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Myrtle Beach", 
                        "country": "United States", 
                        "state": "South Carolina"
                    }, 
                    "name": "Watson Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chattanooga", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }, 
                    "name": "Watson Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Draper", 
                        "country": "United States", 
                        "state": "Utah"
                    }, 
                    "name": "Watson Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas", 
        "overall_contact": {
            "email": "howard.zobrist@watson.com", 
            "last_name": "R. Howard Zobrist, MS PhD", 
            "phone": "801-588-6258"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Absence of bleeding", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Time to absence of bleeding", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02147197"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Watson Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Watson Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}